Monitor for first-patient-dosed announcement (expected early November 2026) and subsequent Phase 1 topline data (~mid-2027). No near-term binary catalyst; stock movement likely limited until proof-of-mechanism readout.
Price Chart
Executive Summary
Equillium received Australian regulatory clearance (HREC approval and TGA clearance) to begin a Phase 1 trial of EQ504, an oral AhR modulator for ulcerative colitis. Dosing of healthy volunteers is expected by early November 2026, with topline proof-of-mechanism data approximately six months later. This is an early-stage, pre-revenue milestone with no financial data or binary catalyst in the near term.
Key Facts
- HREC approval and TGA clearance received for Phase 1 trial of EQ504 in Australia
- First participant dosing expected by early November 2026
- Phase 1 is randomized, double-blind, placebo-controlled, single-center study in healthy subjects
- Topline proof-of-mechanism data anticipated ~6 months after study initiation
- Phase 2 proof-of-concept study in ulcerative colitis targeted for H2 2027, contingent on Phase 1 data
- EQ504 is a potent and selective AhR modulator formulated as an oral, colon-targeted delayed-release drug product
Financial Impact
No financial data disclosed; pre-revenue clinical-stage company
Risk Factors
- Phase 1 trial may fail to demonstrate safety or proof of mechanism
- Competition from existing and emerging therapies for ulcerative colitis
- Company may need additional financing to advance EQ504 through Phase 2
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3374999 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $1.29 | awaiting T+60 | — | $1.25 (+3.10%) |
Oct 26, 2026 today | Press Release | $1.12 | awaiting T+60 | — | $1.25 (+11.58%) |
Oct 5, 2026 21d ago | 8-K | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Oct 5, 2026 21d ago | Press Release | $1.42 | awaiting T+60 | — | $1.25 (−11.97%) |
Sep 29, 2026 27d ago | Press Release | $1.63 | awaiting T+60 | — | $1.25 (−23.08%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.81 $2.21 | ▼ −21.35% | ▼ −25.75% | $1.25 (−55.52%) |
Jun 5, 2026 20w ago | Insider Cluster | $2.77 $2.21 | ▲ +20.40% | ▲ +23.45% | $1.25 (+54.87%) |
May 29, 2026 21w ago | Insider Cluster | $3.08 $2.18 | ▼ −29.22% | ▼ −30.45% | $1.25 (−59.42%) |
May 20, 2026 22w ago | Press Release | $2.21 | awaiting T+60 | — | $1.25 (−43.44%) |
Apr 17, 2026 27w ago | EFFECT | $2.05 $2.76 | ▲ +34.63% | ▲ +28.49% | $1.25 (−39.02%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers